Biopharma patent expiry is the expiration of a patent that protects some aspect of a drug, biologic, formulation, manufacturing process, or method of use.
One patent date is rarely the whole story
A product can be protected by multiple patents with different expiration dates.
Commercial protection can also depend on:
- regulatory exclusivity;
- pediatric exclusivity;
- settlement agreements;
- formulation patents;
- method-of-use patents; and
- pending litigation.
AbbVie example
AbbVie discloses expected expiration dates for significant patents covering major products and separately discusses settlement agreements and potential generic entry timing.
Source:
Patent expiry is a legal protection milestone, not automatically the exact date when generic or biosimilar competition begins.
Part of the Biopharma Development and Commercialization
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- ABBVOpen operating-model research →2 of 16 reviewed concepts in Biopharma Development and CommercializationCommercialization, partnerships, and exclusivity2 of 5 bridge concepts supportedContinue through this bridge:Loss of Exclusivity
Explore other companies in this operating model
These companies are linked to at least two other reviewed concepts in the same operating model, but are not currently linked to this concept. This is broader research navigation, not evidence that the company reports an equivalent metric.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare biopharma stocks
Continue into stock comparison for pipeline stage, regulatory milestones, commercialization economics, concentration, and valuation context.
Explore more topics in the Financial Research Encyclopedia.